Cell Proliferation News and Research

RSS

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

Human amniotic epithelial cells, stem cells derived from human placenta left over from live births and generally discarded, proliferated and differentiated when they interacted with one kind of melatonin receptor, MT1. This potentially therapeutic response occurred when the stem cells were transplanted into laboratory test tube and animal models of stroke. The same cells did not perform similarly when interacting with melatonin receptor MT2.

2 Feb 2011

First commercially available full length human MTOR protein with superior biological activity released

OriGene Technologies, Inc., a gene-centric life sciences company, releases the first commercially available full length human MTOR protein with superior biological activity.

2 Feb 2011

Fibroblasts help 'recruit' immune cells for tumor growth

The most common connective tissue cell in animals is the fibroblast, which plays an important role in healing wounds. But Dr. Neta Erez of Tel Aviv University's Sackler Faculty of Medicine has now demonstrated that fibroblasts can also do a body great harm, helping to "recruit" immune cells for tumor growth.

27 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

19 Jan 2011

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Harbor BioSciences, Inc., a leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals, announced it has licensed the research and development and commercialization rights for three of its products, exclusively in the People's Republic of China and Hong Kong, to China State Institute of Pharmaceutical Industry (CIPI).

18 Jan 2011

Offensive protein generated by HPV handicaps defensive protein made by the human body

An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection.

12 Jan 2011

Researchers discover specific genetic abnormalities in hESC, iPSC lines

A multinational team of researchers led by stem cell scientists at the University of California, San Diego School of Medicine and Scripps Research Institute has documented specific genetic abnormalities that occur in human embryonic and induced pluripotent stem cell lines.

7 Jan 2011

GT Life Sciences and BGI complete CHO-K1 genome sequencing

GT Life Sciences, a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, and BGI, the largest genomics organization in the world, announced that they have successfully completed for the first time the sequencing of the Chinese hamster ovary genome.

6 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Presence of PML molecules could serve to diagnose condition of tumor: Researchers

Cancer cells reproduce by dividing in two, but a molecule known as PML limits how many times this can happen, according to researchers lead by Dr. Gerardo Ferbeyre of the University of Montreal's Department of Biochemistry.

6 Jan 2011

New technique to analyze and quantify changes in protein

A scientist from the Florida campus of The Scripps Research Institute has devised a new method of analyzing and quantifying changes in proteins that result from a common chemical process. The new findings could provide new insights into the effects of a highly destructive form of stress on proteins in various disease models, particularly cancer.

6 Jan 2011

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

Molecular-level insights into how physical activity influences the heart

Everyone knows that exercise comes with metabolic and cardiovascular benefits, but scientists understand surprisingly little about how physical activity influences the heart itself. Now, a new study in the December 23rd issue of Cell, a Cell Press publication, offers some of the first molecular-level insights.

24 Dec 2010

Sequestering GSK3 enzyme leads to stabilization of proteins in cells

The cell signaling pathway known as Wnt, commonly activated in cancers, causes internal membranes within a healthy cell to imprison an enzyme that is vital in degrading proteins, preventing the enzyme from doing its job and affecting the stability of many proteins within the cell, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

24 Dec 2010

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients.

23 Dec 2010

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.

22 Dec 2010

New findings says TRIM24 protein plays active role in breast cancer formation

The recently identified TRIM24 protein plays an active role in pushing normal breast cells into rapid cell proliferation and, potentially, into breast cancer.

16 Dec 2010

Cell Proliferation News and Research

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

First commercially available full length human MTOR protein with superior biological activity released

Fibroblasts help 'recruit' immune cells for tumor growth

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Offensive protein generated by HPV handicaps defensive protein made by the human body

Researchers discover specific genetic abnormalities in hESC, iPSC lines

GT Life Sciences and BGI complete CHO-K1 genome sequencing

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Presence of PML molecules could serve to diagnose condition of tumor: Researchers

New technique to analyze and quantify changes in protein

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Molecular-level insights into how physical activity influences the heart

Sequestering GSK3 enzyme leads to stabilization of proteins in cells

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

New findings says TRIM24 protein plays active role in breast cancer formation

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News